FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to a BCMA-specific chimeric antigen receptor (CAR) containing an IL-6 signalling blocker. Also disclosed is a polynucleotide coding said CAR, as well as a cell containing it. Invention also relates to a pharmaceutical composition containing said cell.
EFFECT: invention is effective for treating multiple myeloma and simultaneous reduction or elimination of cytokine storm syndrome (CRS).
10 cl, 2 dwg, 4 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC CYTOKINE RECEPTORS CARRYING PD-1 ECTODOMAIN | 2020 |
|
RU2828214C2 |
| NUCLEOTIDE SEQUENCE CODING FUSION PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN IL-6R AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IGG4 | 2023 |
|
RU2818329C1 |
| BISPECIFIC ANTIBODIES AND THEIR APPLICATIONS | 2022 |
|
RU2821577C2 |
| NUCLEOTIDE SEQUENCE CODING FUSED PROTEIN CONSISTING OF FUNCTIONAL FRAGMENT OF HUMAN IL-1RA AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IgG4 | 2023 |
|
RU2821896C1 |
| MONOCLONAL ANTIBODIES SPECIFIC TO PROTEIN RUSTICYANIN, AND USE OF ANTIBODIES FOR DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS | 2024 |
|
RU2823344C1 |
| MUS MUSCULUS 5B9 HYBRID CULTIVATED ANIMAL CELLS- A PRODUCER OF MOUSE MONOCLONAL ANTIBODY 5B9, MONOCLONAL MOUSE ANTIBODY 5B9 AND RECOMBINANT CHIMERIC (MOUSE-HUMAN) ANTIBODY XI5B9, NEUTRALIZING RICIN RICINUS COMMUNIS | 2022 |
|
RU2802436C1 |
| SORAFENIB-BASED COMBINATION THERAPY FOR HEPATOCELLULAR CARCINOMA | 2022 |
|
RU2800071C1 |
| NUCLEOTIDE SEQUENCE CODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN PDGFRA AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IGG4 | 2023 |
|
RU2821574C1 |
| MONOCLONAL ANTIBODIES AGAINST THE RECEPTOR-BINDING DOMAIN OF SARS-COV-2 SPIKE PROTEIN AND THEIR ANTIGEN-BINDING FRAGMENTS ENCODING THEIR NUCLEIC ACIDS, AS WELL AS METHODS OF THEIR USE | 2021 |
|
RU2800649C2 |
| MONOCLONAL ANTIBODY IC2 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817697C1 |
